SciSparc (SPRC) Operating Margin (2016 - 2022)

SciSparc (SPRC) posted Operating Margin of 140.07% for Q4 2022, up 525.24% sequentially from 32.94% in Q3 2022.

SciSparc (SPRC) Operating Margin (2016 - 2022) Analysis & Trends

SciSparc has reported Operating Margin for 4 years, with the latest figure at 140.07% in Q4 2022.

Quarterly Operating Margin changed N/A year-over-year to 140.07% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 733.47% (changed N/A YoY) and the FY2025 annual result came in at 978.27%, down 41809.0% from the prior year.
Operating Margin advanced to 140.07% in Q4 2022 per SPRC's latest filing, from 32.94% in the prior quarter.
Over five years, Operating Margin peaked at 140.07% in Q4 2022 and troughed at 371.05% in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Vertex Pharmaceuticals	138.53 Bn	130.68 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	86.34 Bn	78.35 Bn	3.93 Bn	30.15%
3	Argenx Se	64.67 Bn	59.48 Bn	1.37 Bn	32.54%
4	Moderna	59.04 Bn	53.90 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.03 Bn	36.94 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.78 Bn	27.47 Bn	992.69 Mn	17.93%
7	BioNTech SE	27.81 Bn	9.42 Bn	668.28 Mn	-35.57%
8	Insmed	27.21 Bn	26.05 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	26.99 Bn	26.15 Bn	-	19.75%
10	SciSparc	807,202.50	807,202.50	-	-

Download Data